Longitude Capital
  • ABOUT
  • TEAM
  • PORTFOLIO
  • NEWS
  • CONTACT
  • LP LOGIN
Select Page

CG Oncology Announces First Patient Dosed in PIVOT-006 Phase 3 Clinical Trial of Cretostimogene in Intermediate-risk Non-Muscle Invasive Bladder Cancer

by Seini Moimoi | Feb 27, 2024 | Portfolio News

BioAge Announces $170 Million Oversubscribed Series D Financing to Accelerate Development of Obesity and Metabolic Disease Therapeutics

by Seini Moimoi | Feb 13, 2024 | Portfolio News

Endogenex™ Receives IDE Approval to Initiate Pivotal Clinical Study

by Seini Moimoi | Jan 30, 2024 | Portfolio News

Vera Therapeutics Presents Positive 72-Week Data Showing eGFR Stabilization in the Phase 2b ORIGIN Clinical Trial OLE in IgA Nephropathy

by Seini Moimoi | Jan 25, 2024 | Portfolio News

Endeavor BioMedicines Successfully Completes Phase 2a Trial Of ENV-101 In Patients With Idiopathic Pulmonary Fibrosis

by Seini Moimoi | Jan 24, 2024 | Portfolio News

« Older Entries
Next Entries »

Media Contact

Maggie Jamison

mjamison@longitudecapital.com

650-854-5700

  • Facebook
  • X
  • RSS
footer-logo

LP Login

© 2026 Longitude Capital. All rights reserved.
  • Privacy Policy
  • Disclaimer